Apogee Therapeutics ( (APGE) ) has issued an update.
On March 3, 2025, Apogee Therapeutics announced positive interim Phase 1 results from its first-in-human trial of APG990, which exceeded trial objectives and demonstrated potential for extended dosing intervals. The company also reported significant progress in its pipeline, including the accelerated execution of the Phase 2 APEX clinical trial for APG777 and plans for further trials in asthma and eosinophilic esophagitis. Apogee’s strong financial position, with $731.1 million in cash and marketable securities, supports its operations into 2028, despite increased R&D and G&A expenses in 2024.
More about Apogee Therapeutics
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel biologics for inflammatory and immunology markets, including treatments for atopic dermatitis, asthma, eosinophilic esophagitis, and chronic obstructive pulmonary disease.
YTD Price Performance: -33.32%
Average Trading Volume: 541,144
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.84B
For detailed information about APGE stock, go to TipRanks’ Stock Analysis page.